

# NYRx Notice to Providers: Coverage Update Phosphate Binders/Regulators for Members on Dialysis

February 19, 2026

Effective **January 1, 2026**, to align with the Centers for Medicare & Medicaid Services (CMS) policy ([89 FR 89084](#)), drugs in the Phosphate Binders/Regulators [Preferred Drug List \(PDL\)](#) class will no longer be covered as a pharmacy benefit by NYRx for members on dialysis. **Phosphate binders/regulators will be provided by the member’s dialysis center.** Medicaid Fee-for-Service and Medicaid Managed Care dialysis bundled payment rates will be adjusted to account for this change.

Preferred Drugs	Non-Preferred Drugs	Coverage Parameters
<b>XIV. Renal and Genitourinary</b>		
<b>Phosphate Binders/Regulators <sup>CC</sup></b>		
<b>**Effective 1/1/2026, Phosphate Binders/Regulators will no longer be covered by NYRx when used for dialysis. Phosphate Binders/Regulators will be covered as part of the dialysis rate.**</b>		
calcium acetate sevelamer carbonate powder, tablet (gen Renvela)	Auryxia™ ferric citrate 210 mg tablet (gen Auryxia™) Fosrenol® lanthanum carbonate Renvela® tablet, powder pack sevelamer HCl (gen Renagel) Velphoro® Xphozah®	<b>CLINICAL CRITERIA (CC)</b> <ul style="list-style-type: none"> <li>For patients not on dialysis, confirm diagnosis of FDA approved or compendia-supported and Medicaid covered indication</li> </ul>

## What Pharmacy Providers Need to Do

Starting January 1, 2026, new and refill claims submitted to NYRx for a phosphate binder/regulator for members on dialysis will deny with the message “PA required,” however, a prior authorization (PA) is not available for these drugs for these members. **Pharmacies should direct prescribers and members back to the dialysis center to obtain their phosphate binder/regulator.**

In the event of an emergency, where a member cannot obtain a phosphate binder/regulator through a dialysis center, at the discretion of the pharmacist, a pharmacy may follow the process for a [Pharmacy Three-Day Emergency Supply Prior Authorization](#) by calling the NYRx Clinical Call Center at 1-877-309-9493.

## What Prescribers Need to Do

Starting January 1, 2026, prescribers should work directly with dialysis centers to ensure coverage of these drugs for their Medicaid members who are on dialysis. Prescribers should **not send** prescriptions for phosphate binders to the pharmacy to be billed to NYRx if a member is currently on dialysis. Phosphate binders/regulators for patients not on dialysis will continue to be covered by NYRx and will be subject to the [NYRx Preferred Drug Program](#) coverage criteria.

## Additional Information and Resources

- [Updated Implementation Date for APG Weight Adjustment for Phosphate Binders](#)
- [CMS Federal Register](#)
- [NYRx Preferred Drug List](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.

Questions regarding this policy may be emailed to [NYRx@health.ny.gov](mailto:NYRx@health.ny.gov).